Patients who test positive using Labcorp's COVID-19 PCR test will receive information about monoclonal antibody therapeutics with their result.
Additionally, Labcorp's COVID-19 site provides information about treatments and vaccines, including monoclonal antibody therapies, and answers a variety of questions related to testing options.
As of May 7, Labcorp has processed more than 41 m COVID-19 PCR tests.
Monoclonal antibody treatments are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as the virus that causes COVID-19.
Two such treatments currently have emergency use authorization from the US Food and Drug Administration.
People who are at high risk for progressing to severe COVID-19 or hospitalization can potentially reduce their risk of becoming very ill by receiving a monoclonal antibody treatment within the first 10 days of illness.
Early evidence suggests that monoclonal antibody treatments can reduce the amount of SARS-CoV-2, the virus that causes COVID-19, in a person's system, which decreases the likelihood of severe symptoms and hospitalization.
Labcorp's COVID-19 PCR test has not been FDA-cleared or approved; it has been authorized by the FDA under an EUA only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
The test is authorized only for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b) (1) of the Act, 21 USC. § 360bbb-3(b) (1), unless the authorization is terminated or revoked sooner.
Labcorp has diagnostics and drug development capabilities, more than 70,000 employees, and serves clients in more than 100 countries.
HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine